{"id":942408,"date":"2026-03-05T16:05:08","date_gmt":"2026-03-05T21:05:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/optimizerx-reports-strong-fourth-quarter-and-full-year-2025-financial-results\/"},"modified":"2026-03-05T16:05:08","modified_gmt":"2026-03-05T21:05:08","slug":"optimizerx-reports-strong-fourth-quarter-and-full-year-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/optimizerx-reports-strong-fourth-quarter-and-full-year-2025-financial-results\/","title":{"rendered":"OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results"},"content":{"rendered":"
\n\n\n\n\n\n\n\n\n
–\u00a0 \u00a0Q4 revenue of $32.2 million<\/td>\n<\/tr>\n
–\u00a0 \u00a0Q4 gross profit increased 9% year-over-year to $24.1 million<\/td>\n<\/tr>\n
–\u00a0 \u00a0Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively<\/td>\n<\/tr>\n
– \u00a0 Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million<\/td>\n<\/tr>\n
– \u00a0 Paid off an incremental $2 million in principal from term loan during Q4<\/td>\n<\/tr>\n
– \u00a0 OptimizeRx’s Board authorizes a $10 million share repurchase program<\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n<\/table>\n

WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the \u201cCompany\u201d) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2025.<\/p>\n

\n Finan<\/strong>
\n cial Highlights<\/strong>\n <\/p>\n